Anixa Biosciences (ANIX)
(Delayed Data from NSDQ)
$3.10 USD
+0.05 (1.64%)
Updated Apr 18, 2024 04:00 PM ET
After-Market: $3.10 0.00 (0.00%) 7:58 PM ET
4-Sell of 5 4
F Value F Growth F Momentum F VGM
Brokerage Reports
0 items in cart
ANIXA BIOSCIENCES INC [ANIX]
Reports for Purchase
Showing records 1 - 20 ( 34 total )
Company: ANIXA BIOSCIENCES INC
Industry: Business - Services
Phase 1 Ovarian Cancer CAR-T Trial Advances to Second Cohort; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: CHEN Y
Company: ANIXA BIOSCIENCES INC
Industry: Business - Services
Phase 1 Trial of Breast Cancer Vaccine Reports Positive New Data; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: CHEN Y
Company: ANIXA BIOSCIENCES INC
Industry: Business - Services
European Patent Allowed For Ovarian Cancer Vaccine Technology; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: CHEN Y
Company: ANIXA BIOSCIENCES INC
Industry: Business - Services
Ovarian Cancer CAR-T Trial Completes First Cohort Treatment; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: CHEN Y
Company: ANIXA BIOSCIENCES INC
Industry: Business - Services
Company: ANIXA BIOSCIENCES INC
Industry: Business - Services
Ovarian Cancer CAR-T Trial Completes the First Cohort; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: CHEN Y
Company: ANIXA BIOSCIENCES INC
Industry: Business - Services
Additional U.S. Patent Allowed For Ovarian Cancer Vaccine; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: CHEN Y
Company: ANIXA BIOSCIENCES INC
Industry: Business - Services
Canadian Patent Issued for CAR-T Technology; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: CHEN Y
Company: ANIXA BIOSCIENCES INC
Industry: Business - Services
Company: ANIXA BIOSCIENCES INC
Industry: Business - Services
Second Ovarian Cancer Patient Treated in CAR-T Trial; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: CHEN Y
Company: ANIXA BIOSCIENCES INC
Industry: Business - Services
Positive Phase 1a Breast Cancer Vaccine Data Presented; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: CHEN Y
Company: ANIXA BIOSCIENCES INC
Industry: Business - Services
Fiscal 1Q23 Financial Results Reported; Reiterate Buy; Adjusting PT to $12
Provider: H.C. Wainwright & Co., Inc.
Analyst: CHEN Y
Company: ANIXA BIOSCIENCES INC
Industry: Business - Services
New Patent on Breast Cancer Vaccine Allowed; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: CHEN Y
Company: ANIXA BIOSCIENCES INC
Industry: Business - Services
Maximum Tolerated Dose Reached For Breast Cancer Vaccine; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: CHEN Y
Company: ANIXA BIOSCIENCES INC
Industry: Business - Services
Phase 1b Breast Cancer Vaccine Trial Initiated; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: CHEN Y
Company: ANIXA BIOSCIENCES INC
Industry: Business - Services
Ovarian Cancer CAR-T Trial Commences Patient Treatment; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: CHEN Y
Company: ANIXA BIOSCIENCES INC
Industry: Business - Services
Intellectual Property Portfolio Strengthened; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: CHEN Y
Company: ANIXA BIOSCIENCES INC
Industry: Business - Services
Preclinical Data of Ovarian Cancer Vaccine Published; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: CHEN Y
Company: ANIXA BIOSCIENCES INC
Industry: Business - Services
Ovarian Cancer CAR-T Trial Initiated; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: CHEN Y